Relevant bibliographies by topics / Low molecular weight heparin

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Low molecular weight heparin'

Author: Grafiati
Published: 4 June 2021
Last updated: 25 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Low molecular weight heparin.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Low molecular weight heparin"

1

&NA;. "Heparin/low molecular weight heparins." Reactions Weekly &NA;, no. 1414 (2012): 28–29. http://dx.doi.org/10.2165/00128415-201214140-00091.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

&NA;. "Heparin/low-molecular-weight heparins." Reactions Weekly &NA;, no. 1198 (2008): 22. http://dx.doi.org/10.2165/00128415-200811980-00068.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

&NA;. "Heparin/low molecular weight heparins." Reactions Weekly &NA;, no. 1210 (2008): 18. http://dx.doi.org/10.2165/00128415-200812100-00051.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

&NA;. "Heparin/low molecular weight heparins." Reactions Weekly &NA;, no. 1211 (2008): 17–18. http://dx.doi.org/10.2165/00128415-200812110-00053.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

&NA;. "Heparin/low molecular weight heparins." Reactions Weekly &NA;, no. 1211 (2008): 18. http://dx.doi.org/10.2165/00128415-200812110-00056.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

&NA;. "Heparin/low molecular weight heparins." Reactions Weekly &NA;, no. 1277 (2009): 23. http://dx.doi.org/10.2165/00128415-200912770-00068.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

&NA;. "Heparin/low molecular weight heparins." Reactions Weekly &NA;, no. 1231 (2008): 16–17. http://dx.doi.org/10.2165/00128415-200812310-00049.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

&NA;. "Heparin/low molecular weight heparins." Reactions Weekly &NA;, no. 989 (2004): 10. http://dx.doi.org/10.2165/00128415-200409890-00030.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Mulloy, Barbara, Trevor Barrowcliffe, and Elaine Gray. "Heparin and low-molecular-weight heparin." Thrombosis and Haemostasis 99, no. 11 (2008): 807–18. http://dx.doi.org/10.1160/th08-01-0032.

Full text
Abstract:
SummaryHeparin is one of the oldest biological medicines, and has an established place in the prevention and treatment of venous thrombosis. Low-molecular-weight heparins (LMWH) have been developed by several manufacturers and have advantages in terms of pharmacokinetics and convenience of administration. They have been shown to be at least as effective and safe as unfractionated heparin and have replaced the latter in many indications. In this article the chemistry, mechanisms of action, measurement of anticoagulant activities, and clinical status of heparin and LMWH are reviewed.
APA, Harvard, Vancouver, ISO, and other styles
10

Hoppensteadt, Debra, Jeanine M. Walenga, Jawed Fareed, and Rodger L. Bick. "Heparin, low–molecular-weight heparins, and heparin pentasaccharide." Hematology/Oncology Clinics of North America 17, no. 1 (2003): 313–41. http://dx.doi.org/10.1016/s0889-8588(02)00091-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Low molecular weight heparin"

1

Hettiarachchi, Rohan Jagath Kumara. "Venous thromboembolism, cancer and low molecular weight heparin." [S.l. : Amsterdam : s.n.] ; Universiteit van Amsterdam [Host], 2000. http://dare.uva.nl/document/84386.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Matthíasson, Stefán E. "Low molecular weight heparin and dextran in thromboprophylaxis human and experimental studies /." Malmö : Dept. of Surgery, Lund University, Malmö General Hospital, 1994. http://books.google.com/books?id=9OxsAAAAMAAJ.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Vecchietti, D. G. "Low Molecular Weight Heparins : in depth structural characterization to understand their different biological properties." Doctoral thesis, Università degli Studi di Milano, 2008. http://hdl.handle.net/2434/59669.

Full text
Abstract:
Heparin is a linear, heterogeneous, highly sulfated polysaccharide belonging to the family of glycosaminoglycans, endowed with anticoagulant and antithrombotic properties. Its linear chains are made up of 15-200 disaccharide units of N-sulfated or N-acetylated D-glucosamine linked to hexuronic (glucuronic or iduronic) acid. Low molecular weight heparins (LMWHs), developed to circumvent some unwanted side effect of unfractionated heparins (UFH), are obtained from UFH by diverse chemical and enzymatic depolymerisation processes. Fragments generated by cleavage of heparin may therefore structur
APA, Harvard, Vancouver, ISO, and other styles
4

Mauron, Thomas. "Influence of low molecular weight heparin and low molecular weight dextran sulfate on the inhibition of coagulation factor XIa by serpins /." Bern : Hämatologisches Zentrallabor der Universität Inselspital, 1998. http://www.ub.unibe.ch/content/bibliotheken_sammlungen/sondersammlungen/dissen_bestellformular/index_ger.html.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Gandara, Esteban. "Is an Intermediate Dose of LMWH Effective for Secondary Prevention of Recurrent Venous Thromboembolism in Pregnant Patients Diagnosed with Deep Vein Thrombosis or Pulmonary Embolism? Design of a Pilot Study." Thèse, Université d'Ottawa / University of Ottawa, 2012. http://hdl.handle.net/10393/23388.

Full text
Abstract:
Statement of the problem The primary objective of this thesis was to determine the best study design to evaluate the safety and effectiveness of an intermediate dose of low molecular weight heparin for secondary prevention of pregnancy associated VTE (PAVTE). An RCT was deemed unfeasible,so the use of a single arm study with prior evaluation of feasibility with a pilot study is proposed. // Methods - A systematic review was conducted to evaluate the efficacy of current strategies used for secondary prevention of PAVTE.A survey was used to elicit the non-inferiority margin. // Results - The poo
APA, Harvard, Vancouver, ISO, and other styles
6

Holmström, Margareta. "Clinical aspects on treatment of deep venous thrombosis with a low molecular weight heparin /." Stockholm, 1998. http://diss.kib.ki.se/1998/91-628-2989-0/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Näsström, Birgit. "Lipoprotein lipase in hemodialysis patients and healthy controls : effects of heparin /." Umeå : Univ, 2004. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-340.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Steward, David W., John B. Bossaer, Brian Odle, Emily Flores, and Somi Rikhye. "Prescribing of Low-Molecular-Weight Heparin and Warfarin in Patients with Acute Venous Thromboembolism and Active Cancer." Digital Commons @ East Tennessee State University, 2014. https://dc.etsu.edu/etsu-works/2322.

Full text
Abstract:
Background: Malignancy is a significant risk factor for venous thromboembolism (VTE), conferring a 4- to 7-fold increased risk in patients with cancer. Because of its effect on certain tumors, low-molecular-weight heparin (LMWH) has been evaluated as a treatment option for cancer and as an alternative to traditional warfarin therapy in patients with active cancer. LMWH is associated with a reduced recurrence of VTE, fewer adverse bleeding events, and, in some instances, decreased mortality. The American College of Chest Physicians/American Society of Clinical Oncology has recommended LMWH for
APA, Harvard, Vancouver, ISO, and other styles
9

Pranckevičienė, Gabrielė. "Pharmacoepidemiologic assessment of low-molecular-weight heparins utilization in Lithuania and development of pharmacoeconomic model." Doctoral thesis, Lithuanian Academic Libraries Network (LABT), 2014. http://vddb.library.lt/obj/LT-eLABa-0001:E.02~2014~D_20140305_141832-70667.

Full text
Abstract:
In recent years, many countries have struggled with the fact that expenditures on health care are growing much faster than the overall level of wealth. Research objectives: 1) to conduct a meta-analysis of heparins by the means of their efficacy, safety parameters and treatment outcomes; 2) to conduct pharmacoepidemiological assessment of long-term heparins utilization in Lithuania; 3) to develop a pharmacoeconomic cost-minimization model for low-molecular-weight heparins based on reference pricing methodology; 4) to investigate heparins prescribing trends and to evaluate heparins prescription
APA, Harvard, Vancouver, ISO, and other styles
10

Lima, Juliana Pego. "Development of Nanoparticles as Low Molecular Weight Heparins Carriers for Oral Administration." Master's thesis, Faculdade de Farmácia da Universidade do Porto, 2007. http://hdl.handle.net/10216/7486.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Low molecular weight heparin"

1

Barrowcliffe, Trevor W. Low molecular weight heparin. Wiley, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Hyers, Thomas M. Treatment handbook of low-molecular-weight heparin. Science Press, 2000.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Christian, Doutremepuich, ed. Low molecular weight heparins in clinical practice. Dekker, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

1940-, Kher André, Sarret Monique 1938-, and Toulemonde Francis 1926-, eds. Low molecular weight heparin therapy: An evaluation of clinical trials evidence. Marcel Dekker, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Holmer, Erik. Heparin and its low molecular weight derivatives: Basic and applied studies in the development of a new antithrombotic drug. Sveriges Lantbruksuniversitet, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

institutet, Karolinska, ed. Lipoprotein lipase, hepatic lipase and plasma lipolytic activity: Effects of heparin and a low molecular weight heparin fragment (Fragmin®). Acta medica Scandinavica, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Maguire, Jacinta Marie. Low molecular weight heparin regime or unfractionated heparin and as pirin in the treatment of unstable angina. The Author], 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Shukla, Vijay K. Low molecular weight heparins for major orthopedic surgery: A case for clinical outcomes. Canadian Coordinating Office for Health Technology Assessment, 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Kampen, Thorsten U. Low Molecular Weight Organic Semiconductors. Wiley-VCH Verlag GmbH & Co. KGaA, 2010. http://dx.doi.org/10.1002/9783527629978.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Bäckvall, Helena, and Janne Lehtiö, eds. The Low Molecular Weight Proteome. Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-7209-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Low molecular weight heparin"

1

Davis, James W., Dana Forman, La Scienya M. Jackson, et al. "Low Molecular Weight Heparin." In Encyclopedia of Intensive Care Medicine. Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-642-00418-6_716.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Pineo, G. F., and R. D. Hull. "Low Molecular Weight Heparin." In Antithrombotics. Springer Berlin Heidelberg, 1999. http://dx.doi.org/10.1007/978-3-642-59942-2_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Malloy, Rhynn J., Jessica Rimsans, Megan Rhoten, Katelyn Sylvester, and John Fanikos. "Unfractionated Heparin and Low-Molecular-Weight Heparin." In Anticoagulation Therapy. Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-73709-6_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Stromich, Ashley. "Unfractionated Heparin and Low Molecular Weight Heparin." In Anticoagulation Management. Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-22602-6_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Combs, David J., and Lisa Leffert. "Low Molecular Weight Heparin, Unfractionated Heparin and Neuraxial Anaesthesia." In Quick Hits in Obstetric Anesthesia. Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-72487-0_49.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Gray, Elaine. "Standardisation of Unfractionated and Low-Molecular-Weight Heparin." In Heparin - A Century of Progress. Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-23056-1_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Guerrini, Marco, and Antonella Bisio. "Low-Molecular-Weight Heparins: Differential Characterization/Physical Characterization." In Heparin - A Century of Progress. Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-23056-1_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Elliott, C. Gregory. "Low Molecular Weight Heparins." In Pulmonary Embolism. Springer Japan, 1999. http://dx.doi.org/10.1007/978-4-431-66893-0_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Mousa, Shaker A. "Heparin and Low-Molecular Weight Heparins in Thrombosis and Beyond." In Anticoagulants, Antiplatelets, and Thrombolytics. Humana Press, 2010. http://dx.doi.org/10.1007/978-1-60761-803-4_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Iqbal, Zafar, Omar Hasan, and Marc Cohen. "Unfractionated Heparin and Low Molecular Weight Heparin in Ischemic Heart Disease." In Therapeutic Advances in Thrombosis. Blackwell Publishing Ltd., 2012. http://dx.doi.org/10.1002/9781118410875.ch8.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Low molecular weight heparin"

1

Ordu, Y., J. Augustin, E. V. Hodenberg, V. Bode, and J. Harenberg. "COMPARATIVE CLINICAL PHARMACOLOGY OF LOW MOLECULAR WEIGHT HEPARINS IN MAN." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643228.

Full text
Abstract:
Low molecular weight (LMW) heparins are obtained by diffent chemical procedures from conventional pig intestinal mucosa heparin. The LMW heparins differ in their molecular weight distribution and physicochemical properties. Therefore, we report of comparative studies on the anticoagulant and lipolytic effects of low molecular weight heparins in man.The following LMW heparins were used: BM 21-23 (Braun, Melsungen, FRG), CY 216 (Choay Laboratories, Paris, France), Heparin NM (Sandoz, Niimberg, FRG), Kabi 2165 (Kabi Vitrum AB, Stockholm, Sweden), RD Heparin (Hepar Industries, Franklin, US A), nor
APA, Harvard, Vancouver, ISO, and other styles
2

Fareed, J., J. M. Walenga, D. Hoppensteadt, R. N. Emanuele, and A. Racanell. "PHARMACOLOGIC INEQUIVALENCE OF LOW MOLECULAR WEIGHT HEPARINS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644163.

Full text
Abstract:
Compared to unfractionated heparin, low molecular weight heparins (LMWHs) have been found to exhibit marked variations in in vitro effects due to variations in molecular weight and structure. Moreover, when the in vitro potency of these agents is equally adjusted bypharmacopeial assay (current and proposed) wide variations in the in vivo responses have been noted. These variations were strongly dependent on the route of administration. Utilizing defined animal models, a systematic comparative study of the in vivo responses of seven commercial LMWHs was undertaken. Choay Fraxiparine (CY 216} Ch
APA, Harvard, Vancouver, ISO, and other styles
3

Lasker, S. E., B. Y. Lee, and R. E. Madden. "LOW MOLECULAR WEIGHT HEPARINS s ORAL ABSORPTION IN MONKEYS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644855.

Full text
Abstract:
An orally administered low molecular weight heparin-like derivative of the commercial polydisperse polysaccharide is desirable clinically. The dissociation of antithrombotic properties and the induction of bleeding as well as minimal effect on platelet function are characteristics of some low-molecular weight heparins; however the circulating level of the anti Xa activity associated with demonstrable theraputic efficacy is not yet defined.The availability of a variety of low molecular weight heparins provided us with the opportunity to evaluate the gastrointestinal absorption characteristics o
APA, Harvard, Vancouver, ISO, and other styles
4

Zimmerman, R. A., C. T. Rieger, K. Hübner, C. W. Harenber, and W. Kübler. "EXPERIMENTAL THROMBUS FORMATION AND HAEMOSTASIS OF DIFFERENT LOW MOLECULAR WEIGHT HEPARINS AND DOSAGES." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644162.

Full text
Abstract:
Low molecular weight heparin induces a higher anti factor Xa (a-Xa) and a lower antithrombin activity in plasma in comparison to conventional heparin. From this constellation a more pronounced antithrombotic effect and a minor incidence of bleeding Complications has been suggested.Therefore the antithrombotic activity of heparins was studied in a standardized experimental thrombosis model in rabbits. Three low molecular weight heparins with a mean molecular weight of 4.200 (heparin I),4.000 (heparin II),4.600 Dalton (heparin III) and standard heparin were tested at different dosages in 120 exp
APA, Harvard, Vancouver, ISO, and other styles
5

Mätzsch, T., D. Berggvist, U. Hedner, B. Nilsson, and P. Østergaard. "INDUCTION OF OSTEOPOROSIS IN RATS BY STANDARD HEPARIN AND LOW MOLECULAR WEIGHT HEPARIN." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1642930.

Full text
Abstract:
Long-term treatment with heparin can induce osteoporosis. This complication is suspected to be related to the dosage of heparin rather than to duration of therapy, but the mechanism by which heparin induces osteoporosis is unknown. In a previous study we reported the same degree of reduction in mineral bone mass in rats after treatment with 2 IU heparm/g bw for 33 and 65 days (Thromb Haemostas 1986,56:293-4). Using the same animal model we compared the effect of a high-dose standard heparin (SH) and a low molecular weight heparin (LMWH) in a high and a low dose on the mineral bone mass in the
APA, Harvard, Vancouver, ISO, and other styles
6

Giese, Ch, A. Knodler, R. Zimmermann, and J. Harenberg. "A NEW ONE STAGE CLOTTING ASSAY FOR HEPARIN AND LOW MOLECULAR WEIGHT HEPARINS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644851.

Full text
Abstract:
Heparin and its low molecular weight (LMW) derivatives are usually measured by chromogenic or fluorogenic synthetic substrate assays and by coagulation tests. Since the activated partial thromboplastin time (aPTT) and thrombin clotting time (TCT) are insensitive to LMW heparins, we report here of data obtained with heptest, a new one stage modification of the original heparin in plasma assay of Yin. The assay was compared with the antifactor Xa chromogenic substrate S2222 method, the TCT and aPTT tests in 100 patients receiving unfractionated pig intestinal mucosa heparin and 100 patients trea
APA, Harvard, Vancouver, ISO, and other styles
7

Sakuragawa, N., T. Shimotori, and K. Takahashi. "COMPARATIVE STUDIES ON ANTITHROMBIN III AFFINITY OF LOW MOLECULAR WEIGHT HEPARIN AND UNFRACTIONATED HEPARIN." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644365.

Full text
Abstract:
Purpose: Low molecular weight(LMW)heparin shows stronger antifactor Xa(F-Xa) and weaker anti-thrombin(TH) activities compared with unfractionated(UF) heparin, and shows less bleeding tendency in the cases of clinical use. These characteristics were surmised to be depend on antithrombin III(AT-III) affinity of the heparin. Materials and methods: LMW heparin(Kabi and Pharmuka), UF heparin (Novo) and heparin cofactor II(HC-II) purified by our method were used. AT-III affinity column chromatography with 0.1 M Tris-buffer (pH 7.4)-NaCl 0.02 to 2.5 M linear gradient was performed. From the point of
APA, Harvard, Vancouver, ISO, and other styles
8

Briel, R. C., P. C. Hermann, and P. Doller. "LOW MOLECULAR WEIGHT HEPARIN (FRAGMIN) PROPHYLAXIS IN GYNECOLOGIC SURGERY." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643223.

Full text
Abstract:
In a prospective, randomized study patients undergoing hysterectomy were treated either by the low molecular weight heparin Fragmin or by the combination of unfractionated sodium heparin + dihydroergotamin (HDHE). The dosage in the Fragmin group was 2× 2500 anti Xa-U on day 1 = day of surgery, from day 2-8: 1× 5000 anti Xa-U, in the HDHE-group from day 1-8: 2× 5000 IU heparin + 0.5 mg DHE. 99 patients were randomly allocated to prophylaxis with Fragmin, 101 to HDHE prophylaxis. 95 and 96 respectively were evaluated, the others excluded for different reasons. The 2 groups were comparable for ge
APA, Harvard, Vancouver, ISO, and other styles
9

Emanuele, R. M., and J. Fareed. "THE EFFECT OF MOLECULAR WEIGHT ON THE RELATIVE BIOAVAILABILITY OF HEPARIN." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644179.

Full text
Abstract:
Three fractions of different molecular weight (M. W.) were obtained from gel-filtration of porcine mucosal heparin. These fractions along with unfractionated and a low M. W. heparin (CY 216) were compared for relative bioavailability in primates (Macaca mulatta: n = 5). The M. W.'s of all fractions were determined using high performance liquid chromatography - gel permeation and characterizied in terms of mean M. W., peak M. W. and M. W. distribution. Area under the plasma concentration time curve (AUC) was calculated by the trapezoidal method after intravenous and subcutaneous administration
APA, Harvard, Vancouver, ISO, and other styles
10

Chong, B. H., F. Ismail, J. Cade, A. S. Gallus, S. Gordon, and C. N. Chesterman. "HEPARIN-INDUCED THROMBOCYTOPENIA: IN VITRO STUDIES WITH LOW MOLECULAR WEIGHT HEPARINOID, ORG 10172." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643926.

Full text
Abstract:
Heparin-induced thrombocytopenia (HIT), an adverse effect of heparin therapy, may be associated with serious thrombosis resulting in severe disability or death. An IgG heparin-dependent antibody may be demonstrated in HIT by platelet aggregation studies with patient serum/plasma and standard (s) heparin. A recent study showed high cross-reactivity of the antibody with low molecular weight (LMW) heparins as most of the 22 patient sera tested gave a positive reaction with various LMW heparins including CY222, CY216, PK10169 and Kabi 2165 (Messmore HL et al, Blood 64(5), 1984 suppl). However, cro
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Low molecular weight heparin"

1

Chen, Chen, Peng Chen, Xia Liu, and Hua Li. Combined 5-Fluorouracil and Low Molecular Weight Heparin for the Prevention of Postoperative Proliferative Vitreoretinopathy in Patients with Retinal Detachment. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2021. http://dx.doi.org/10.37766/inplasy2021.8.0117.

Full text
Abstract:
Review question / Objective: The aim of this meta-analysis is to evaluate the efficacy and safety of intraoperative infusion of combined 5-fluorouracil and low molecular weight heparin (LMWH) for the prevention of postoperative proliferative vitreoretinopathy in patients with retinal detachment. Condition being studied: Postoperative proliferative vitreoretinopathy (PVR) is the primary cause of failure of retinal reattachment surgery. 5-fluorouracil (5-FU) inhibits the proliferation of fibroblasts, and suppresses collagen contraction. On the other hand, heparin reduces fibrin exudation, and in
APA, Harvard, Vancouver, ISO, and other styles
2

Wei, Qingqing, Weiying Wang, Guobin Miao, et al. Aspirin Versus Low-Molecular-Weight Heparin for Venous Thromboembolism Prophylaxis in Patients after Postoperative Joint Surgery: A Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2023. http://dx.doi.org/10.37766/inplasy2023.2.0117.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

huang, kun, yan sun, and hai jiang. Effect of low molecular weight heparin combined with aspirin on pregnancy outcomes of unexplained recurrent abortion: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2023. http://dx.doi.org/10.37766/inplasy2023.10.0005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Wang, Lin, Xiang wen Yao, and Hongxue Qu. Aspirin versus low molecular weight heparin for the avoidance of venous thromboembolism in major orthopedic operation: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2023. http://dx.doi.org/10.37766/inplasy2023.5.0081.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Rungjirajittranon, Tarinee, Weerapat Owattanapanich, Yingyong Chinthammitr, Theera Ruchutrakool, and Bundarika Suwanawiboon. Direct oral anticoagulants versus low-molecular-weight heparin for acute treatment of venous thromboembolism in patients with gastrointestinal cancer: A systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2021. http://dx.doi.org/10.37766/inplasy2021.8.0113.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Roberts, Christine Cardinal, Alan Graham, Martin Nemer, et al. Physical Properties of Low-Molecular Weight Polydimethylsiloxane Fluids. Office of Scientific and Technical Information (OSTI), 2017. http://dx.doi.org/10.2172/1343365.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Gao, H. Crosslinked, flexible, low-molecular-weight polyacrylamide gels for mobility control. Office of Scientific and Technical Information (OSTI), 1989. http://dx.doi.org/10.2172/5405561.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Scharf, Michael E., Sam N. Nguyen, Cheol Song, and Phillip G. Koehler. Bioassay for Volatile Low Molecular Weight Insecticides and Methods of Use. Defense Technical Information Center, 2007. http://dx.doi.org/10.21236/ada605489.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Woods, W. T., and Jr. Mechanisms of Action of Low Molecular Weight Toxins in the Cardiovascular System. Defense Technical Information Center, 1987. http://dx.doi.org/10.21236/ada225113.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Ren, Tong. Hydrolytic and Peroxyhydrolytic Degradation of Nerve Agent Analogs with Low Molecular Weight Bimetallic Catalysts. Defense Technical Information Center, 2005. http://dx.doi.org/10.21236/ada429791.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Low molecular weight heparin' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography